Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scinai ImmunotherapeuticsFRA:2F5 -0.94%20 Net Margin % is 731.44% as of Mar. 2026, which is 1436% above its 10-year median of 47.62. GuruFocus rates FRA:2F5 with a GF Score™ of 20/100. The stock has 4 warning signs investors should review. Among 942 Biotechnology companies, Scinai Immunotherapeutics ranks better than 98.2% on this metric.
The historical rank and industry rank for Scinai Immunotherapeutics's Net Margin % or its related term are showing as below:
FRA:2F5'
s Net Margin % Range Over the Past 10 Years
Min: -633.64 Med: 47.62 Max: 728.88
Current: 147.93
FRA:2F5's Net Margin % is ranked better than 98.2% of 942
companies
in the Biotechnology industry
Industry Median: -89.445
vs FRA:2F5: 147.93
Scinai Immunotherapeutics (FRA:2F5) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Scinai Immunotherapeutics Net Margin % Related Terms
Scinai Immunotherapeutics Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2F5 vs ABPO, ISCO, ZVSA: Net Margin % Comparison
For the Biotechnology subindustry, Scinai Immunotherapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinai Immunotherapeutics Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scinai Immunotherapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Scinai Immunotherapeutics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinai Immunotherapeutics (FRA:2F5) has a Net Margin % of 731.44% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Scinai Immunotherapeutics and its competitors. This is 1436% above median its historical median of 47.62. According to the industry distribution chart, Scinai Immunotherapeutics ranks #17 out of 942 companies in the Biotechnology industry, placing it in the top 1.8%.
Is Scinai Immunotherapeutics' Net Margin % too high?
Scinai Immunotherapeutics' current Net Margin % of 731.44% is 1436% above median its 10-year median of 47.62. Based on the distribution chart, Scinai Immunotherapeutics ranks #17 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Scinai Immunotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scinai Immunotherapeutics' Net Margin % compare to ABPO and ISCO?
According to the Biotechnology industry distribution chart, Scinai Immunotherapeutics ranks #17 out of 942 companies for Net Margin %. This places Scinai Immunotherapeutics in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Scinai Immunotherapeutics and its competitors. Scinai Immunotherapeutics's current Net Margin % is 731.44%, which is 1436% above median its own 10-year median of 47.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinai Immunotherapeutics stock overvalued right now?
Scinai Immunotherapeutics (FRA:2F5) has a current Net Margin % of 731.44%. The current Net Margin % is 731.44%, which is 1436% above median its 10-year median of 47.62. Scinai Immunotherapeutics' overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Scinai Immunotherapeutics (FRA:2F5), the current Net Margin % is 731.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
20GF Score
Get the complete analysis for FRA:2F5
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2F5 has been successfully added to your 
